BREAST CANCER RESISTANCE PROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 347

60. Komatani, H, Kotani, H, Hara, Y, Nakagawa, R, Matsumoto, M, Arakawa, H, and
Nishimura, S. 2001. Identification of breast cancer resistant protein/mitoxantrone
resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-
506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer
Res 61:2827-2832.
61. Ma, J, Maliepaard, M, Nooter, K, Loos, WJ, Kolker, HJ, Verweij, J, Stoter, G, and Schel-
lens, JH. 1998. Reduced cellular accumulation of topotecan: a novel mechanism of resis-
tance in a human ovarian cancer cell line. Br J Cancer 77:1645-1652.
62. Maliepaard, M, van Gastelen, MA, de Jong, LA, Pluim, D, van Waardenburg, RC,
Ruevekamp-Helmers, MC, Floot, BG, and Schellens, JH. 1999. Overexpression of the
BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res
59:4559-4563.
63. Kawabata, S, Oka, M, Shiozawa, K, Tsukamoto, K, Nakatomi, K, Soda, H, Fukuda,
M, Ikegami, Y, Sugahara, K, Yamada, Y, et al. 2001. Breast cancer resistance protein
directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun
280:1216-1223.
64. Ishii, M, Iwahana, M, Mitsui, I, Minami, M, Imagawa, S, Tohgo, A, and Ejima, A.
2000. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various
drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant vari-
ants derived from the human lung cancer cell line PC-6. Anticancer Drugs 11:353-
362.
65. van Hattum, AH, Hoogsteen, IJ, Schluper, HM, Maliepaard, M, Scheffer, GL, Scheper,
RJ, Kohlhagen, G, Pommier, Y, Pinedo, HM, and Boven, E. 2002. Induction of breast
cancer resistance protein by the camptothecin derivative DX-8951f is associated with
minor reduction of antitumour activity. Br J Cancer 87:665-672.
66. van Hattum, AH, Schluper, HM, Hausheer, FH, Pinedo, HM, and Boven, E. 2002. Novel
camptothecin derivative BNP1350 in experimental human ovarian cancer: determination
of efficacy and possible mechanisms of resistance. Int J Cancer 100:22-29.
67. Volk, EL, Farley, KM, Wu, Y, Li, F, Robey, RW, and Schneider, E. 2002. Overexpression
of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer
Res 62:5035-5040.
68. Robey, RW, Medina-Perez, WY, Nishiyama, K, Lahusen, T, Miyake, K, Litman, T,
Senderowicz, AM, Ross, DD, and Bates, SE. 2001. Overexpression of the ATP-binding
cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human
breast cancer cells. Clin Cancer Res 7:145-152.
69. Nakanishi, T, Karp, JE, Tan, M, Doyle, LA, Peters, T, Yang, W, Wei, D, and Ross, DD.
2003. Quantitative analysis of breast cancer resistance protein and cellular resistance to
flavopiridol in acute leukemia patients. Clin Cancer Res 9:3320-3328.
70. Erlichman, C, Boerner, SA, Hallgren, CG, Spieker, R, Wang, XY, James, CD, Scheffer,
GL, Maliepaard, M, Ross, DD, Bible, KC, and Kaufmann, SH. 2001. The HER tyrosine
kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and
topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res
61:739-748.
71. Elkind, NB, Szentpetery, Z, Apati, A, Ozvegy-Laczka, C, Varady, G, Ujhelly, O, Szabo,
K, Homolya, L, Varadi, A, Buday, L, et al. 2005. Multidrug transporter ABCG2 pre-
vents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa
(ZD1839, Gefitinib). Cancer Res 65:1770-1777.